Adult obesity rates drop across Peterborough
The adult obesity rate in Peterborough has "dropped considerably", according to a new figures.A report to be put before Cambridgeshire and Peterborough's joint health and well-being board and Integrated Care Partnership shows the latest figures on child and adult obesity rates, and highlights what needs to be done going forward.The Cambridgeshire rate for adult obesity at 61.1% is slightly lower than the national rate, while Peterborough's rate (64%) has "dropped considerably" and is now equal to the national rate, it says.The report will be discussed at a meeting on Friday.
The report shows the overall rate of childhood overweight/obesity has stabilised across Cambridgeshire and Peterborough. Cambridgeshire's reception age obesity rate has dropped to about the Covid pandemic level, but Peterborough's rate reflects its historical trend of fluctuating, the Local Democracy Reporting Service said.Both Peterborough and Fenland stand out as having rates above the national average in childhood obesity in reception age and Year 6 age children.The report states: "Tackling obesity is complex and requires a comprehensive and system-wide approach. It also means aligning to national policy, for example the Child Health Action Plan and Health Mission."
A consultation is currently under way looking at the city council's public health behaviour change service budget, as the city council needs to shave £440,000 a year off its discretionary public health services.While some of the services it provides are mandatory, such as substance misuse, health visitors and sexual health, others, such as services which aim to change behaviours which lead to poorer health outcomes are not.It is proposed the savings are made by reducing spending on health trainers and adult weight management services, where evidence shows that the impact of these services on weight reduction in adults is low.Instead, support would be focused on activities which prevent people becoming overweight, including advice around diet and exercise. People would continue to be able to receive weight management support from the NHS.Dr Shabina Qayyum, the council's cabinet member for public health and adult social care, said that despite an "uplift in the region of £400,000 in our public health grant for the current financial year", it was not enough to cover the demands of a growing population.She said: "We have looked at the services we have a choice over providing and it is those where the impact is lowest, and where there are alternatives offered by the NHS, where we are proposing to reduce funding."Friday's meeting will consider obesity in the region and the areas that need to be addressed by the system in order to maintain and accelerate progress.
Follow Peterborough news on BBC Sounds, Facebook, Instagram and X.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
30 minutes ago
- Telegraph
NHS patients to receive drug that destroys cancer from inside
A so-called 'Trojan Horse' drug that destroys blood cancer from within is set to be rolled out to thousands of NHS patients. The health service will be the first in the world to make the drug available to patients with multiple myeloma – an incurable cancer of the bone marrow. The drug, called belantamab mafadotin, was developed in the UK and has been dubbed a 'Trojan Horse' therapy because it tricks cancer cells into absorbing it before killing them from within. While the cancer is incurable, treatment is designed to extend people's lives by as much as possible while minimising the impact of side effects and on quality of life. In trials, cancer progression was delayed by three years on average in those taking the drug, which was three times longer than the most common treatment. Around 1,500 patients a year in England will benefit after the treatment was approved by the National Institute for Health and Care Excellence on Thursday. The drug will be offered to patients whose cancer has progressed or not responded to the first choice of treatment using another drug, lenalidomide. Patients who are prescribed the drug will receive it via an infusion once every three weeks in combination with two other cancer treatments.
The Guardian
44 minutes ago
- The Guardian
Blood cancer patients in England first in world to be offered ‘Trojan horse' drug
Thousands of patients in England with blood cancer will become the first in the world to be offered a pioneering 'Trojan horse' drug that sneaks inside cancer cells and wipes them out. In guidance published on Friday, the National Institute for Health and Care Excellence (Nice) gave the green light to belantamab mafodotin, which can halt the advance of multiple myeloma for three times as long as standard treatments. The targeted therapy, which is given as an infusion every three weeks with other cancer drugs, is a special type of antibody drug that targets and attaches to cancer cells. It has been described as a Trojan horse treatment because it works by being taken into a cancer cell and unleashing a high concentration of a lethal molecule to destroy the cell from inside. Prof Peter Johnson, NHS England's national clinical director for cancer, said the drug would be life-changing for patients and their families. 'Myeloma is an aggressive type of blood cancer, but we have seen a steady improvement in the outlook for patients over recent years as we have introduced new targeted therapies,' he said. 'I am delighted that patients in England will be the first to benefit from this new treatment, which has the potential to keep cancer at bay for years longer, giving people the chance of more precious time with friends and family.' About 1,500 patients a year in England with multiple myeloma, an incurable cancer of the bone marrow, will benefit from the treatment, also known as Blenrep and made by GlaxoSmithKline. Health officials said the drug would be offered to patients whose cancer had progressed or failed to respond to another first-line treatment. Shelagh McKinlay, the director of research and advocacy at the blood cancer charity Myeloma UK, said it was fantastic to see the NHS become the first healthcare system in the world to roll out the drug. 'We have been working very hard for the last year to get this treatment approved and we know it will transform the lives of thousands of people with myeloma,' she said. Paul Silvester, 60, from Sheffield, described the impact of the drug as amazing after he was diagnosed with myeloma in 2023. After the first treatment he received failed to stop his cancer progressing, he was given belantamab mafodotin through an early access programme at the Royal Hallamshire hospital. 'I feel like this treatment has brought the party balloons back in the house. It has been amazing – within the first two or three weeks, after the first dose, I was in remission,' he said. Trials suggest the treatment, in combination with bortezomib and dexamethasone, delays progression of the disease by an average of three years, compared with one year for patients taking the commonly used drug daratumumab along with the other treatments. Helen Knight, the director of medicines evaluation at Nice, said: 'This recommendation demonstrates our commitment to getting the best care to patients fast, while ensuring value for the taxpayer.' The health minister Karin Smyth said: 'This groundbreaking therapy puts the NHS at the forefront of cancer innovation. By harnessing cutting-edge 'Trojan horse' technology, we're offering new hope to blood cancer patients across the country.'
BBC News
an hour ago
- BBC News
Kidney Research UK boss appointed OBE at special ceremony
A charity chief executive who has overseen more than £71m being ploughed into research for kidney disease has become an OBE at a special Currie, from Northampton, has been at Peterborough-based Kidney Research UK for more than 12 Wednesday she visited Windsor Castle to be appointed an Officer of the Order of the British Empire (OBE) by the Prince of Wales, which she called a "very special moment".She was recognised in the King's New Year Honours list earlier this year for her services to people affected by the disease. "To represent the kidney community in such a setting was incredibly humbling," she explained. "This honour helps raise the profile of a disease that affects one-in-ten people in the UK, can have devastating consequences for those who reach kidney failure, but is still overlooked. "I'm grateful for the recognition, and more determined than ever to keep pushing for change."There are more than 7.2m people living in the UK with kidney disease, including more than 80,000 in Northamptonshire, the charity Currie has worked to invest millions into research, as well as improve awareness of the disease. Follow Northamptonshire news on BBC Sounds, Facebook, Instagram and X.
